Department of Commerce
Foreign-Trade Zones Board
- [B-48-2026]
Patheon Manufacturing Services LLC submitted a notification of proposed production activity to the FTZ Board (the Board) for its facility in Greenville, North Carolina within FTZ 214. The notification conforming to the ( printed page 29451) requirements of the Board's regulations (15 CFR 400.22) was received on May 14, 2026.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be limited to the specific foreign-status material(s)/component(s) and specific finished product(s) described in the submitted notification (summarized below) and subsequently authorized by the Board. The benefits that may stem from conducting production activity under FTZ procedures are explained in the background section of the Board's website—accessible via www.trade.gov/ftz.
The proposed finished products include: Opdualag (pre-filled syringes containing Relatlimab and Nivolumab in aqueous solution) (duty-free).
The proposed foreign-status materials/components include: Relatlimab (an aqueous solution drug targeting immune checkpoint LAG-3 in melanoma therapy); and Nivolumab-rmbw (an aqueous solution targeting immunotherapy treatment against cancer cells) (duty-free).
The request indicates that certain materials/components are subject to duties under section 301 of the Trade Act of 1974 (section 301), depending on the country of origin. The applicable section 301 decisions require subject merchandise to be admitted to FTZs in privileged foreign status (19 CFR 146.41).
Public comment is invited from interested parties. Submissions shall be addressed to the Board's Executive Secretary and sent to: ftz@trade.gov. The closing period for their receipt is June 29, 2026.
A copy of the notification will be available for public inspection in the “Online FTZ Information System” section of the Board's website.
For further information, contact John Frye at John.Frye@trade.gov.
Dated: May 15, 2026.
Elizabeth Whiteman,
Executive Secretary.